The Oxford vaccine, manufactured by AstraZeneca in England, is showing an “encouraging” immune response among older adults in their 60s and 70s.
BBC News notes that 560 healthy adults are part of the study, which is in its second stage.
If successful, the Oxford vaccine would be easier to distribute to the public because it doesn’t need to be stored at very cold temperatures like the Pfizer-BioNTech vaccine.
The UK government has ordered 100 million doses of the Oxford vaccine, compared to 40 million doses of the Pfizer-BioNTech vaccine and five million of the Moderna vaccine.
(Source: BBC News)